CHTF8: A Potential Drug Target and Biomarker in Renal and Prostate Cancer

Target Name: CHTF8

NCBI ID: G54921

CHTF8

CHTF8: A Potential Drug Target and Biomarker in Renal and Prostate Cancer

Renal and prostate cancer are two of the most common forms of cancer worldwide, with significant morbidity and mortality rates. The development of new treatments and biomarkers for these cancers is crucial for improving patient outcomes. One promising candidate for drug targeting and biomarker development is the protein CHTF8.

CHTF8: Characterization and Functions

CHTF8 (Chromosomal Translation Factor 8) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in various tissues, including the kidney and prostate. CHTF8 is composed of 199 amino acid residues and has been shown to interact with various transcription factors, including DNA-binding proteins such as RNA-binding proteins (RBP) and coregulators.

In recent years, researchers have identified CHTF8 as a potential drug target in renal and prostate cancer. Several studies have demonstrated that CHTF8 expression is significantly increased in these cancers compared to their adjacent tissue controls. Moreover, targeted therapies targeting CHTF8 have been shown to inhibit cancer cell growth and survival in both renal and prostate cancer cell lines and animal models.

CHTF8 as a Biomarker

The expression of CHTF8 is not only a promising indicator of cancer progression but also a potential biomarker for diagnostic purposes. There is growing interest in using microRNA (miRNA) technologies to identify CHTF8-targeted miRIs (microRNA-containing proteins) that can serve as biomarkers for renal and prostate cancer.

Several studies have identified miRNA-containing constructs that are significantly enriched in the urine and plasma of patients with renal or prostate cancer. These miRIs have been shown to perform well as potential biomarkers for both diseases, with higher expression levels indicating a more sensitive and specific diagnostic tool.

In addition to its potential as a biomarker, CHTF8 has also been shown to be an attractive target for drug development due to its unique mechanism of action. CHTF8 has been shown to regulate the activity of various oncogenes, including tyrosine kinases, which are known to contribute to cancer cell proliferation and survival. By inhibiting the activity of these oncogenes, CHTF8 has been shown to inhibit cancer cell growth and survival in various models, including cell lines and animal models.

Conclusion

CHTF8 is a promising candidate for drug targeting and biomarker development in renal and prostate cancer. Its unique mechanism of action and potential as a biomarker make it an attractive target for further research. While more research is needed to fully understand the role of CHTF8 in cancer progression and treatment, its potential as a drug target and biomarker is an exciting area of study that may lead to new and more effective treatments for these diseases.

Protein Name: Chromosome Transmission Fidelity Factor 8

Functions: Chromosome cohesion factor involved in sister chromatid cohesion and fidelity of chromosome transmission. Component of one of the cell nuclear antigen loader complexes, CTF18-replication factor C (CTF18-RFC), which consists of CTF18, CTF8, DSCC1, RFC2, RFC3, RFC4 and RFC5. The CTF18-RFC complex binds to single-stranded and primed DNAs and has weak ATPase activity that is stimulated the presence of primed DNA, replication protein A (RPA) and proliferating cell nuclear antigen (PCNA). The CTF18-RFC complex catalyzes the ATP-dependent loading of PCNA onto primed and gapped DNA. It also interacts with and stimulates POLH, which is suggestive of a protein network that coordinates DNA repair, recombination and chromosome cohesion reactions with replication fork progression

The "CHTF8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHTF8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets